Abstract

Pressure overload induces cardiac hypertrophy through activation of Janus kinase 2 (Jak2), however, the underlying mechanisms remain largely unknown. In the current study, we tested whether histone deacetylase 2 (HDAC2) was involved in the process. We found that angiotensin II (Ang-II)-induced re-expression of fetal genes (Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP)) in cultured cardiomyocytes was prevented by the Jak2 inhibitor AG-490 and HDAC2 inhibitor Trichostatin-A (TSA), or by Jak2/HDAC2 siRNA knockdown. On the other hand, myocardial cells with Jak2 or HDAC2 over-expression were hyper-sensitive to Ang-II. In vivo, pressure overload by transverse aorta binding (AB) induced a significant cardiac hypertrophic response as well as re-expression of ANP and BNP in mice heart, which were markedly reduced by AG-490 and TSA. Significantly, AG-490, the Jak2 inhibitor, largely suppressed pressure overload-/Ang-II-induced HDAC2 nuclear exportation in vivo and in vitro. Meanwhile, TSA or HDAC2 siRNA knockdown reduced Ang-II-induced ANP/BNP expression in Jak2 over-expressed H9c2 cardiomyocytes. Together, these results suggest that HDAC2 might be a downstream effector of Jak2 to mediate cardiac hypertrophic response by pressure overload or Ang-II.

Highlights

  • Pressure overload-induced cardiac hypertrophy is mediated partly by activation of Janus kinase 2(Jak2) [1,2]

  • In order to test the role of Jak2 and histone deacetylase 2 (HDAC2) in cardiac hypertrophy response, siRNA strategy was utilized to selectively knockdown Jak2 or HDAC2 in H9c2 cardiomyocytes

  • In H9c2 cells, which was significantly inhibited by Jak2 or HDAC2 siRNA knockdown (Figure 1E–G)

Read more

Summary

Introduction

Pressure overload-induced cardiac hypertrophy is mediated partly by activation of Janus kinase 2(Jak2) [1,2]. Pressure overload-induced cardiac hypertrophy is mediated partly by activation of Janus kinase 2. Under biochemical and/or mechanic stresses, cardiac Jak is activated mainly through the increased circulating angiotensin II (Ang-II) [3,4]. Treatment with the Jak inhibitor AG-490 prevented the hypertrophic response, indicating that Jak is important in the development of cardiac hypertrophy [5]. Recent studies show that transverse aorta binding (AB)-induced cardiac hypertrophy is associated with increased expression/activity of histone deacetylases (HDACs) [2]. Studies demonstrated that Trichostatin-A (TSA), a HDAC2 inhibitor, attenuated the development of cardiac hypertrophy [10,11]. We found that HDAC2 might be a downstream effector of Jak to mediate cardiac hypertrophic response

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.